Travere licenses civorebrutinib from Everest in $1.14B kidney deal
Bottom line
Travere Therapeutics has licensed civorebrutinib, also known as EVER001, from Everest Medicines in a deal worth up to about $1.14 billion, adding an investigational oral BTK inhibitor to its rare kidney disease pipeline. Under the agreement announced June 2, 2026, Everest will receive $112.5 million upfront and could earn roughly $1.03 billion in development, regulatory, and commercial milestones across as many as five indications. Travere gets exclusive rights outside China and certain East and Southeast Asian countries, with plans to develop the drug in primary membranous nephropathy, immune-mediated FSGS, and minimal change disease. (prnewswire.com)
Why it matters: For veterinary professionals, this is mainly a signal about where nephrology drug development capital is moving. Travere is doubling down on immune-mediated kidney disease after building its franchise around FILSPARI, and civorebrutinib brings an oral mechanism aimed at B-cell signaling and autoantibody-driven disease. Early Phase 1b/2a data from China in primary membranous nephropathy showed reductions in anti-PLA2R autoantibodies and proteinuria, with mostly Grade 1-2 treatment-related adverse events, which helps explain why Travere was willing to make a large business development bet. (prnewswire.com)
What to watch: Watch for Travere’s development plan outside Asia, especially whether it moves quickly into later-stage studies in primary membranous nephropathy and into additional immune-mediated kidney indications. (prnewswire.com)
Travere Therapeutics is expanding deeper into rare kidney disease by licensing civorebrutinib from Everest Medicines in a transaction valued at up to about $1.14 billion. The June 2, 2026 deal gives Travere exclusive development and commercialization rights outside China and certain East and Southeast Asian markets for the investigational oral BTK inhibitor, which Everest has been advancing as EVER001. Everest will receive $112.5 million upfront, plus the potential for about $1.03 billion in milestone payments. (prnewswire.com)
The move fits Travere’s broader strategy of building a focused nephrology portfolio. The company already has a commercial foothold in rare kidney disease with FILSPARI, which received full FDA approval for proteinuria reduction in FSGS in April 2026, and has continued to position itself as a specialist in serious glomerular disorders. Adding civorebrutinib gives Travere another shot on goal in immune-mediated kidney disease, this time with a small-molecule BTK approach rather than an endothelin-angiotensin pathway therapy. (travere.com)
Civorebrutinib is being framed by both companies as a potential “pipeline-in-a-product” asset because of its possible use across multiple autoimmune kidney diseases. According to Everest and Travere, the initial focus will include primary membranous nephropathy, immune-mediated FSGS, and minimal change disease, with room to expand into additional indications. In its 8-K disclosure, Travere said the license covers essentially all prophylactic, diagnostic, and therapeutic uses in the covered territory, underscoring how broad the strategic bet is. (prnewswire.com)
The scientific rationale comes from Everest’s ongoing Phase 1b/2a study in China in patients with biopsy-proven primary membranous nephropathy who were positive for anti-PLA2R autoantibodies. In an update released July 1, 2025, Everest said the study enrolled 31 patients and that EVER001 was generally safe and well tolerated, with the most common treatment-related adverse events reported as Grade 1-2. The company also reported early reductions in anti-PLA2R autoantibodies and improving clinical remission rates through follow-up, while kidney function remained stable. Everest said outside experts had recommended discussions with the FDA about a Phase III program, though that recommendation should be read as early-stage enthusiasm rather than a regulatory commitment. (everestmedicines.com)
Both companies used the announcement to emphasize strategic fit. Everest chairman Yifang Wu said the partnership brings together kidney disease development and commercialization expertise, while Travere CEO Eric Dube described civorebrutinib as a complementary addition to the company’s rare kidney disease portfolio. Those comments are expected in deal announcements, but they also reflect a real market dynamic: nephrology has become more active in recent years as developers pursue targeted therapies for smaller, biologically defined renal diseases that previously had few approved options. (prnewswire.com)
Why it matters: For veterinary professionals, this is less about an immediate practice impact and more about a useful read on translational and industry direction. The deal highlights strong investor and pharma interest in immune-mediated kidney disease, particularly therapies aimed at antibody-driven pathology and proteinuria reduction. While civorebrutinib is a human medicine candidate, the biology around B-cell signaling, immune-mediated renal injury, and the search for steroid-sparing oral therapies will sound familiar to clinicians who manage glomerular disease in companion animals. It’s also another example of how companies are placing large bets on narrower, specialty indications when early mechanistic and biomarker data look convincing. (prnewswire.com)
What to watch: The next key questions are whether Travere outlines a clear ex-Asia clinical timeline, how aggressively it expands into FSGS and minimal change disease, and whether regulators appear receptive to a pivotal path in primary membranous nephropathy. Just as important, the field will be watching whether BTK inhibition can deliver durable efficacy without the safety baggage that limited some earlier agents in adjacent categories. (prnewswire.com)